- Home
- CRSP vs SLGN Comparison
CRSP vs SLGN Comparison
Compare CRSP & SLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRSP
- SLGN
- Stock Information
- Founded
- CRSP 2013
- SLGN 1987
- Country
- CRSP Switzerland
- SLGN United States
- Employees
- CRSP N/A
- SLGN N/A
- Industry
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- SLGN Containers/Packaging
- Sector
- CRSP Health Care
- SLGN Industrials
- Exchange
- CRSP Nasdaq
- SLGN Nasdaq
- Market Cap
- CRSP 5.6B
- SLGN 4.6B
- IPO Year
- CRSP 2016
- SLGN 1997
- Fundamental
- Price
- CRSP $67.35
- SLGN $44.46
- Analyst Decision
- CRSP Buy
- SLGN Strong Buy
- Analyst Count
- CRSP 18
- SLGN 9
- Target Price
- CRSP $73.47
- SLGN $60.11
- AVG Volume (30 Days)
- CRSP 2.7M
- SLGN 1.0M
- Earning Date
- CRSP 11-04-2025
- SLGN 10-29-2025
- Dividend Yield
- CRSP N/A
- SLGN 1.79%
- EPS Growth
- CRSP N/A
- SLGN N/A
- EPS
- CRSP N/A
- SLGN 2.81
- Revenue
- CRSP $38,050,000.00
- SLGN $6,162,113,000.00
- Revenue This Year
- CRSP N/A
- SLGN $11.86
- Revenue Next Year
- CRSP $391.94
- SLGN $2.75
- P/E Ratio
- CRSP N/A
- SLGN $15.90
- Revenue Growth
- CRSP N/A
- SLGN 5.49
- 52 Week Low
- CRSP $30.04
- SLGN $41.30
- 52 Week High
- CRSP $78.48
- SLGN $58.14
- Technical
- Relative Strength Index (RSI)
- CRSP 50.50
- SLGN 56.43
- Support Level
- CRSP $64.80
- SLGN $44.13
- Resistance Level
- CRSP $75.06
- SLGN $45.17
- Average True Range (ATR)
- CRSP 4.55
- SLGN 0.90
- MACD
- CRSP -0.96
- SLGN 0.34
- Stochastic Oscillator
- CRSP 18.64
- SLGN 78.59
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
About SLGN Silgan Holdings Inc.
Silgan Holdings manufactures about half of the metal food containers in North America. Its major customers include Campbell Soup, Nestle, and Del Monte. Silgan's other business segments include plastic dispensers and containers for personal and healthcare products and a closures business that manufactures metal and plastic lids and caps.